Date: 2013-07-16
Type of information: Collaboration agreement
Compound: integrated molecular diagnostic testing services
Company: MDX Health (Belgium) - HistoGeneX (Belgium)
Therapeutic area: Cancer - Oncology
Type agreement: collaboration
Action mechanism:
Disease:
Details: * On July 16, 2013, MDxHealth and HistoGeneX have announced the commencement of a pharmaco molecular diagnostic services collaboration. The collaboration enables MDxHealth to combine its epigenetic technologies with HistoGeneX\'s well-established pharmaco diagnostic services to provide to pharmaceutical companies and oncologists with integrated molecular diagnostic testing services. HistoGeneX\'s laboratory in Belgium will also perform MGMT service testing on behalf of MDxHealth\'s current and future clients.
MDxHealth develops and commercializes advanced epigenetic tests for cancer assessment and the personalized treatment of patients. The company\'s first commercial product, ConfirmMDx™ for Prostate Cancer, has been shown to help distinguish patients who have a true-negative biopsy from those who may have undetected cancer. MDxHealth has recently completed a multinational phase III study using its proprietary MGMT methylation test, and numerous completed and ongoing Phase I and II clinical trials, MDxHealth has demonstrated biomarker development and clinical trials management capabilities within the pharmaceutical communityHistoGeneX is a molecular pathology company providing histology, pathology and molecular diagnostic services for pharmaceutical and hospital clients, including extensive biobanking capabilities, clinical trial diagnostics and research services.
Financial terms:
Latest news:
